Cachexia is a severe wasting syndrome where the body breaks down its own muscle and fat, driven by an underlying chronic illness. It goes far beyond normal weight loss. The defining feature is involuntary loss of at least 5% of body weight over 12 months, and unlike starvation, eating more food cannot fully reverse it. Cachexia is estimated to affect up to 80% of people with advanced cancer and directly causes up to 30% of cancer deaths, often through heart or respiratory failure as the body’s muscles deteriorate.
How Cachexia Differs From Starvation
This distinction matters because it shapes everything about how cachexia is understood and treated. When a healthy person stops eating, the body responds predictably: appetite increases, metabolism slows down to conserve energy, and the body preferentially burns fat while sparing muscle for as long as possible. These are survival mechanisms, and they work. Refeeding reverses the process.
Cachexia does the opposite at nearly every level. Instead of ramping up hunger, it suppresses appetite. Instead of slowing metabolism to conserve energy, the body maintains or even increases its metabolic rate, burning through calories faster. Instead of protecting muscle, it aggressively breaks down both muscle and fat tissue simultaneously. The brain and body essentially work against their own survival. This is why nutritional supplementation alone cannot fully reverse cachexia, and why simply giving someone more food, however important for comfort and quality of life, does not solve the underlying problem.
What Drives the Muscle Breakdown
Cachexia is fundamentally an inflammatory condition. The underlying disease, whether cancer, heart failure, or another chronic illness, triggers the immune system to flood the body with inflammatory signaling molecules. Two of the most significant are tumor necrosis factor-alpha and interleukin-6. These molecules interfere with muscle in multiple ways at once: they block the body’s ability to build new muscle protein, they activate systems that actively dismantle existing muscle fibers, and they impair the muscle’s ability to repair and regenerate itself.
The effects cascade further. Inflammation also triggers increased levels of a protein called myostatin, which acts as a brake on muscle growth. It alters how the body processes amino acids (the building blocks of protein), making them less available for muscle maintenance. And it reprograms how tissues use energy, creating wasteful metabolic cycles that burn calories without producing useful work. The result is a body that is simultaneously starving at the cellular level and unable to use the nutrients it does receive.
Which Diseases Cause Cachexia
Cancer is the condition most commonly associated with cachexia, with 50 to 80% of people with advanced cancer developing it. Pancreatic, lung, and gastrointestinal cancers carry especially high rates. But cachexia is not exclusively a cancer problem.
In end-stage chronic heart failure, cachexia prevalence ranges from 5 to 15%. It also appears in the later stages of chronic obstructive pulmonary disease (COPD), where roughly 35% of moderate-stage patients show signs of wasting. Chronic kidney disease and rheumatoid arthritis are additional triggers. In each case, the same inflammatory mechanisms are at work, though the specific disease creates its own pattern of tissue loss and metabolic disruption.
The Three Stages
Cachexia develops progressively, and an international consensus framework divides it into three stages based on how much weight has been lost and how far the body has been depleted.
- Pre-cachexia: Weight loss greater than 1 kilogram but less than 5% of body weight. At this point, metabolic changes and mild inflammation are already detectable even though the person may not look visibly different. This is the window where intervention has the most potential.
- Cachexia: Weight loss greater than 5%, or greater than 2% in someone who already has a low body mass index (under 20) or reduced muscle mass. Fatigue, reduced appetite, and noticeable physical changes are typically present.
- Refractory cachexia: Weight loss exceeding 15% with a BMI below 23, or weight loss exceeding 20% with a BMI below 27. At this stage, the underlying disease is no longer responding to treatment, metabolism is severely disrupted, and the expected survival time is less than three months. The focus of care shifts from reversing wasting to managing symptoms and maintaining comfort.
What It Feels Like
The physical experience of cachexia extends well beyond the number on the scale. People describe profound fatigue that does not improve with rest, weakness that makes everyday tasks like climbing stairs or opening jars difficult, and a persistent lack of appetite or even aversion to food. Clothes stop fitting. The face and limbs can appear gaunt. These changes happen even when the person is eating, which can be deeply confusing and demoralizing.
The psychological toll is substantial. Research into the lived experience of cachexia reveals a pattern of emotional and social impacts that affect both patients and the people who care for them. Patients report loss of independence, negative changes in body image (especially among younger people), feelings of helplessness, and intrusive thoughts about death. Visible wasting can feel like a public marker of illness, leading to social withdrawal and a sense of stigma.
For families, cachexia often creates painful conflict around food. Caregivers instinctively want to feed the person they love, viewing food as care and nourishment. When the patient cannot or does not want to eat, it can feel like rejection on both sides. Studies across multiple countries have found that the symptoms of cachexia disrupt daily routines, force role changes within families, and reduce opportunities for normal social interaction. One researcher described a “weight loss taboo,” where patients, caregivers, and even healthcare professionals avoid discussing the visible decline because none of them know what to do about it.
How Cachexia Is Identified
Diagnosis relies on documented weight loss alongside evidence of an underlying chronic disease. The core criteria are a loss of more than 5% of body weight over the preceding 12 months, or a BMI under 20, combined with at least three of the following: loss of muscle mass, loss of body fat, fatigue and weakness, and signs of inflammation in blood tests.
For muscle loss specifically, a simple screening questionnaire called the SARC-F asks five questions about strength, ability to walk, ability to rise from a chair, ability to climb stairs, and history of falls. Each is scored from 0 to 2, with a total score of 3 or higher suggesting significant muscle loss. It takes less than a minute and requires no equipment, making it useful as a first-pass screen. In one study of older hospitalized patients, a positive SARC-F score was associated with a more than fourfold increase in the risk of rehospitalization.
Treatment Options and Their Limits
There is no single treatment that reverses cachexia, and this remains one of the most frustrating realities of the condition. The most effective approach combines multiple strategies: addressing the underlying disease, optimizing nutrition, encouraging physical activity when possible, and in some cases using medications to stimulate appetite.
On the nutrition side, current recommendations for cancer patients with cachexia suggest a protein intake of 1.4 to 2 grams per kilogram of body weight per day. For a 150-pound person, that translates to roughly 95 to 136 grams of protein daily, which is significantly higher than what most people eat. Research suggests that intakes below 1.4 grams per kilogram are associated with continued muscle loss. Omega-3 fatty acids from fish oil and vitamin D supplementation have shown modest benefits in some studies, particularly for preserving muscle mass in people with lung cancer. The challenge is practical: many people with cachexia have little appetite, and reaching these protein targets is difficult. In one clinical trial aiming for 2 grams per kilogram per day, only about 35% of participants actually achieved that intake.
Two medications are approved in the United States specifically for appetite stimulation in wasting: megestrol acetate, a hormonal drug originally developed for breast cancer that was found to cause weight gain as a side effect, and dronabinol, a synthetic cannabinoid. Megestrol can increase appetite and body weight, but the weight gained tends to be primarily fat rather than muscle, and it carries risks including blood clots and blood sugar problems. Dronabinol may help with appetite and nausea but produces less weight gain overall. Neither drug addresses the underlying metabolic disruption that defines cachexia.
Exercise, particularly resistance training, is one of the few interventions that directly targets muscle preservation. Even modest activity can help maintain strength and function, though the fatigue and weakness of cachexia make exercise programs difficult to sustain. The current consensus favors starting physical activity early, ideally during the pre-cachexia stage, before significant muscle loss has occurred.
Why Early Recognition Matters
Cachexia becomes increasingly difficult to treat as it progresses. By the refractory stage, the metabolic disruption is so severe that the body can no longer respond meaningfully to nutritional or pharmacological interventions. This makes the pre-cachexia window critical. Small, unexplained weight changes in someone with a chronic illness deserve attention, not reassurance. A loss of even a few pounds, combined with fatigue or reduced appetite, can signal the beginning of a process that is far easier to slow down than to reverse.